A biopsy is a tissue or cell sample taken from any part of the patient’s body and examined in the lab for the detection of cancer. Liquid biopsy offers a real-time approach for the treatment of breast cancer. It is used for the collection and analysis of a sample of blood taken from the patient. Liquid biopsy uses body fluids as a sample for analysis, primarily blood. It analyses the presence of tumor cell-derived biomarkers such as circulating tumor cells, cell-free DNA (cfDNA) and their cargo proteins, and circulating cell-free RNA (cfRNA). A liquid biopsy is a noninvasive, simple, and cost-effective diagnostic tool for cancer. The amount of circulating biomarkers differ among cancer patients and healthy individuals. Therefore, these circulating biomarkers act as an important tool for both early diagnosis and monitoring of the progression of disease in advanced cancer stages to analyse the heterogeneity of tumor cells. Breast cancer is considered to be the second most common malignancy in the world, and therefore, liquid biopsy is a very important tool for breast cancer diagnosis and determination.

According to the World Health Organization (WHO), breast cancer is the most frequently occurring cancer among women. It affects 2.1 million women each year and results in the highest number of cancer-related deaths among women. In 2018, it was evaluated that 627,000 women died from breast cancer, i.e. around 15% of all cancer-related deaths among women. While rates of breast cancer are higher among women in more developed regions, rates are elevating in nearly every region globally.

Key drivers of the breast cancer liquid biopsy market include rise in the prevalence of breast cancer, increase in propensity for non-invasive procedures, rise in awareness about cancer, increase in health care expenditure,  and initiatives and measures taken by government and global health organizations. Moreover, intensive research and development in the field of cancer, technological advancements, and an inclination toward personalized medicine are expected to enhance the growth of the market. However, insufficiency of trained professionals, high cost of the tests, and fewer reimbursement policies are expected to hinder the global breast cancer liquid biopsy market.

Based on circulating biomarkers, the global breast cancer liquid biopsy market can be classified into cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other circulating biomarkers. The cell-free DNA (cfDNA) segment is expected to hold a prominent share of the breast cancer liquid biopsy market. This is because of rise in research in breast cancer using cfDNA for the diagnosis of the disease and therapeutic monitoring. In terms of end-user, the global breast cancer liquid biopsy market can be categorized into reference laboratories, hospitals and physician laboratories, and other end-users. Other end-users comprise research institutes, academic research laboratories, pathology laboratories, etc. Reference laboratories is expected to be a prominent end-user segment, accounting for a significant share of the breast cancer liquid biopsy market. This is due to a rise in the number of liquid biopsy test samples received by reference laboratories for genetic testing because of their well-equipped set-up.

Based on geography, the global breast cancer liquid biopsy market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.  North America and Europe accounted for a prominent share of the global breast cancer liquid biopsy market due to the presence of a number of biopharmaceutical companies research and academic institutes. Asia Pacific is expected to be a rapidly expanding region of the breast cancer liquid biopsy market due to a large population base, increased prevalence of cancer, and rise in investments by leading market players and hospitals.

Key players operating in the global breast cancer liquid biopsy market are Qiagen, Bio-Rad Laboratories, Inc.,  F. Hoffmann-La Roche Ltd,  Myriad Genetics, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Genomic Health, Menarini Silicon Biosystems, Cynvenio Biosystems, Inc., Guardant Health, INC , Biodesix, Inc., and Isogen Life Science B.V. among others. In order to gain a competitive advantage in the market, key players are actively involved in various growth strategies such as agreements, partnerships and collaborations, and new product development.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Breast Cancer Liquid Biopsy Market

Pre Book